Press release from Companies
Published: 2011-07-07 15:49:24
WntResearch AB (publ) has submitted a new patent that protects the use of its drug candidate Foxy-5 for the treatment of prostate cancer. The patent also presents methods for diagnosis of recurrent prostate cancer.
As inventors and authors of the new clinical as well as in-vitro studies that form the basis for WntResearch patent application is the company's CSO, Tommy Andersson, and Anders Bjartell, professor and consultant at the Department of Urology, Skåne University Hospital. The project is in an early phase but is based on a sound scientific basis. Continued development will focus on proof of concept studies, in-vivo. CEO Bert Junno comments: "Prostate cancer is one of the predominant forms of cancer disease worldwide and treatment of aggresive forms with metastatic spread is an area in need of new active drugs that in particular can reduce the number of deaths in prostate cancer. Being able to offer treatment to prevent metastatic disease is in line with WntResearch strategy. Even if the project is in an early phase and requires more verification, I think that this will significantly increase the value of WntResearch total offering to the pharmaceutical industry. " Facts about prostate cancer: Prostate cancer is the most common form of cancer in Sweden with an incidence of more than 10000 new cases annually. It is also the most common cancer-related cause of death in men with approximately 2500 cases per year. The diagnosis, treatment and surgical procedures today are highly effective against the primary tumor, however, it still remains to find an effective anti-metastatic treatment, something that WntResearch hopes to offer in the future. WntResearch AB: WntResearch (WNT.ST) is listed on the Aktietorget stock exchange and the business is based on research from Lund University. The focus and purpose of WntResearch is to develop new drugs against metastatic cancers. The company has two major development projects, Foxy-5 and Box-5. The main project is the Foxy-5, which is currently being tested in in vivo models and is planned to start and complete the Phase 1 clinical trials of metastatic cancer in 2012. For more information contact: Bert Junno, CEO WntResearch AB (publ) Tel: 031-707-772209 E-mail: firstname.lastname@example.org